Resistant cells in acute myelogenous leukemia (AML) activate sphingosine kinase 1 (SPHK1) and acid ceramidase (AC), and they display increased OXPHOS, promoting drug resistance. This evidence concerns the gene SPHK1 and acute myeloid leukemia.